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Summary.-The effect of the nitroimidazoles misonidazole, Ro-05-9963, RGW-608
and metronidazole on nerve conduction velocity (NCV) were measured in the
anaesthetized mouse. The compounds were administered by i.p. injection either as a
single dose of 1 mg/g (only0O5 mg/g for RGW-608) or in 36 fractions of0O15 mg/g over
18 days (only 4 fractions in 2 days for RGW-608). After single doses a reduction in
nerve conduction velocity was seen with all the compounds except metronidazole,
which had no significant effect. During chronic exposure, a reduction in NCV occurred
towards the endofthe course ofinjections. All compounds produced aneffect, although
RGW-608 was the most neurotoxic, giving the largest reduction in NCV after only
4 injections. After the end of chronic exposure to misonidazole, Ro-05-9963 and
metronidazole, recovery to normal took 2-3 weeks.
As DRUGS which sensitize hypoxic cells
to radiation become more widely used in
the treatment of cancer it is increasingly
important to maximize the benefit they
may give to the patient. The relationship
between sensitizer enhancement ratio and
drug concentration has been established
for many compounds both in vitro (Adams
et al., 1971; Chapman et al., 1972; Asquith
et al., 1974) and in viro (Denekamp et at.,
1974; Rauth & Kaufman, 1975; McNally
et al., 1978) and it is clear that greater
sensitization of hypoxic cells is achieved
by higher concentrations of drug. How-
ever, it was evident from the first clinical
trials (Urtasun et al., 1977; Dische
et al., 1977; Kogelnik et al., 1978) using
misonidazole, the most promising radio-
sensitizer to be developed so far, that
the dose of drug which can be tolerated
would be limited by its neurotoxicity. In
all cases the peripheral sensory nerves
were affected, first inducing symptoms of
paraesthesia in the feet and hands. Only
at higher doses were effects on the central
nervous system (convulsions) seen (Dische
et al., 1977). Misonidazole is not the only
potential radiosensitizer to cause neuro-
logical disturbances. Most nitroaromatic
compounds when given in high doses,
either as radiosensitizers or as chemo-
therapeutic agents, have produced peri-
pheral neuropathy in man. These include
metronidazole and some nitrofurans
(LeQuesne, 1975; Coxon & Pallis, 1976).
In man, minor sensory neurological
effects arereported verbally bythe patient,
but no satisfactory neurological end-point
has been developed so far using a small
laboratory animal. The present experi-
ments were extensions of the attempt to
develop a technique for measuring con-
duction velocity in peripheral nerves of
the mouse (Hirst et al., 1978) with suffi-
cient accuracy for the effects of clinically
relevant doses of radiosensitizers to be
measured.
The importance of reduction potential
in determining the sensitizing efficiency
and aerobic cytotoxicity of many nitro-
aromatic compounds has been demon-
strated by Adams et al. (1976a, b) in vitro,1D. G. HIRST, 13. VOJNOVIC ANI) B. HOBSON
but other chemnical properties may also be
involved in determining their effect in
vivo. In particular, the lipid solubility may
influence uptake and excretion, and may
also be relevant to the action of the com-
pounds in tissue with a high fat content,
such as myelinated nerves. Consequently,
4 drugs with differing octanol/water par-
tition coefficients were selected for the
present study (Table). For structural
formulae see Adams et al. (1978a). The
reduction potentials of the 3 2-nitro-
imidazoles are very similar; metronidazole,
a 5-nitroimidazole, has a higher reduction
potential, i.e. it is less electron-affinic.
MIATERIALS AND MIETHODS
Motor-nerve conduction velocity Mwas
measured in the sciatic nerve of mice using a
modification of the technique first described
by Helmholz in 1850 and used recently to
measure nerve conduction in the rat (Snyder
et al., 1977). A muscle w-as used as the trans-
ducer to measure the time takenforan impulse
to travel from the point of stimulationi along
a motor nerve.
Female CBA mice 12-15 A-eeks old -were
anaesthetized -with penthrane and their
sciatic nerve and soleus muscle were exposed
surgically. The nerve wNas stimulated through
glass micropipettes at 2 points separated
by an accurately measured distance (typically
about 10 mm) and the electrical activity in
the muscle produced by each impulse w-as
recorded. The delav between each stimulus
and its corresponding muscle action potential
represented the time taken for conduction
from the point of stimulation to the neuro-
muscular junction, for chemical neuro-
mnuscular transmission. and for propagation
ofthe muscle action potential to the recording
probe placed on the muscle surface. By sub-
tracting the total coniduction times -when
stimulating at the twro different points, the
time taken for the impulse to travel the
distance between two stimulating electrodes
was obtained. A typical oscilloscope recording
ofthe two events is sho-wn in Fig. 1.
The details of the technique used in the
present study differ from those described
previously (Hirst et al., 1978) only in the
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FIG. 1.- A tracing of ain oscilloscope recordiing of 2 muiscle action potentials obtained by seqtuential
stimulation thiouigh the 2 micro-electrocles. Delay betwreen stimuli 10 s. The lower tiace is a
magnification of the early part of the 2 events (thick line in upper trace). Oscilloscope gainis and
sweep speeds appear at the top of the display. Reproduced from Hirst et al., 1978.
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FIG. 2.-The effect of temperature on
in control animals. NCV is plotted a
nerve temperature measured with a th
couple probe. Values from different a]
are shown by different symbols.
method of measuring time delays
present experiments a threshold
(Appendix I) was used to monitor t]
action potential, and differences in t
were measured electronically, as o
measuring them from a photograj
oscilloscope trace.
The propagation of a nerve imr
temperature-dependent process, an
temperature of the nerves could no
trolled accurately in the present
experiments, an appropriate correcti
be made. Fig. 2 shows the calculal
conduction velocity (NCV) in a
control animals plotted against the
ture reading from a thermocouple
contact with the nerve. The slop
regression line was 2-3 m/sec/°C. Tt
mental temperatures lay within t]
wide range 22-30°C and factors of
0 95 and 1-40 were applied to corre
chosen standard temperature of 23°
The compounds were given both
doses of 1 mg/g (except RGW-608 v
given at 0 5 mg/g) or as 2 fraction
mg/g/day for 18 days. This sche
chosen lecause it was predicted to
same integrated exposure to mis
(see Appendix II) (allowing for th
half-life in the mouse) as that rec
patients in a recent clinical trial (Dis
1977) in which 6 fractions of mis
were administered in 18 days. The t
administered in the twTo species is, (
different. In the present experimen
drugs were dissolved in sterile isotonic saline
and administered by i.p. injection. The con-
0 o centration of drug in the injected solutions
was 30 mg/ml in the single-dose experiments & and 22-5 mg/ml in the multiple-fraction
£ ' experiments. In the case ofmetronidazole the
solution had to be warmed to about 40°C
shortly before injection to ensure that the
compound was completely dissolved.
RESULTS
32 U. The effect of single injections of 4 nitro-
imidazoles on nerve conduction velocity
(NCV) is shown in Fig. 3. Misonidazole,
i NCV Ro-05-9963 and RGW-608 all caused a
tgainst reduction in NCV, with the minimum
ieirmo- velocities being recorded at 0-5-2 h after
administration. The greatest reduction in
NCV (to 72% of normal) was seen after
In the misonidazole, although it was not possible
detector to make an identical comparison of the
he muscle neurotoxicity of RGW-608, since it was
ime delay given at halfthe concentration ofthe other
pposed to compounds because ofits greater toxicity. )h of the The mean NCV in control animals of
)ulse i'S a 39.6J 1 7 mi/s wassignificantlyhigher than
id as the the velocity reported in a previous experi-
t be con- ment (Hirst et al., 1978) and this is attri-
series of buted to sex and age differences in the
ion had to mice used (12-15-week-old females in the
ted nerve present study and 5-6-week-old males in
group of the previous experiment). The magnitude
tempera- and time course of the reduction in NCV
placed in after misonidazole did not differ signi-
)e of the ficantly, however, from that reported
lie experi- previously. Normal NCV values were
hbertheer obtained by 8 h after injection of 3 of the
Fct to the compounds, but not after misonidazole.
'C. A residual effect of misonidazole was still
as single detectable 16 h after injection, although
vhich was this had disappeared by 5 days. After
iS of 0-15 1 mg/g of metronidazole no significant
dule was changes were observed up to 16 h.
give the Changes in NCV during and after
;onidazole chronic administration of misonidazole, e shorter Ro-05-9963, metronidazole and RGW-608
ceived by (all at a dose of 0-15 mg/g every 12 h) are ,che et al.,9
,onidazole shown in Fig. 4. Nerve conduction veloci-
total dose ties are shown as apercentage ofthe values
of course, for animals receiving the same quantity of
Lts all the isotonic saline as drug-treated animals
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FIG. 3.-Changes in NCV after single i.p. injections of 4 nitroimidazoles. Shaded area shows control
range. Error bars represent s.e.
TABLE-Some physical and biological properties of the compounds tested
Compound
Misonidazole
Ro-05-9963
RGW-608
Metronidazole
Cytotoxicity in vitro (mM)
LD5omg/g I
A
single dose Single dose* Chronict
1.8a lib 1.3c
2.9a 12b 1.3b
0.4a 20b 0-75b
3.5a 60b 6-5c
Octanol/H20
partition coeff.
0*43d
0-lld
3. 4e
096d
* Concentration required to reduce survival to 75% in 2 h.
t Concentration required to reduce survival to 50% in 7-14 days.
a Sheldon (personal communication).
b Adams et al. (1978b).
c Adams et al. (1976a).
dAdams et al. (1976b).
e Adams et al. (1978a).
(i.e. 0-2 ml x 2 daily). NCV in saline-
control animals increased significantlv (by
20%) during the course of injections, but
returned to within the normal range by 14
days after the end of the injections. The
fluctuation was unexpected and leads to
the conclusion that prolonged injection of
NaCl creates an ion imbalance which per-
turbs the process of nerve-impulse
propagation.
RGW-608 proved to be more toxic in
vivo (see Table) than would be predicted
from its in vitro cytotoxicity (Adams et at.,
1978b). Animals tested 12 h after only 4
injections, showed a severe reduction in
NCV (to 69% of saline control). This
dramatic effect is not surprising in view of
the relatively high toxicity of the com-
pound which probably causes death
through damage to the nervous system.
The 3 other compounds produced no
reduction in NCV relative to controls 12 h
after the 18th injection, but by 12 h
after the 36th injection misonidazole and
metronidazole had reduced NCV signi-
ficantly to 83% and 85% of control. The
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FIG. 4.-Changes in NCV during and after multiple i.p. injections (arrowed) of 4 nitroimidazoles.
Drug dose was 0-15 mg/g/injection. Values ± s.e. are expressed as a % ofmean control value at each
time of testing. Control range shown shaded.
reduction in NCV after Ro-05-9963 at this
time was not significant. By 3-5 days after
the last injection a significant reduction in
NCV was recorded in all drug-treated
groups. The biggest effect was a reduction
to 75% after metronidazole. By 7*5 and
14-5 days after thelastinjection, allgroups
had values withinthe controlrange, except
those animals tested after misonidazole
which showed an "overshoot" to supra-
normal values.
DISCUSSION
In the development of new radiosensi-
tizers, neurotoxicity appears to be one of
the most important limiting factors. At
present, very little is known about the
chemical properties which determine the
degree ofneurotoxicity shown in vivo by a
given compound.
It is well known that the aerobic cyto-
toxicity of nitroaromatic compounds is
strongly dependent on reduction potential
(Adams et al., 1976b; 1978b). Fig. 5(a, b)
shows the maximum reduction in NCV
(as a % ofthe control value) after a single
injection of misonidazole, metronidazole,
Ro-05-9963 and RGW-608, plotted as a
function of aerobic toxicity, and octanol/
water partition coefficient (Adams et al.,
1978a, b). There is a clear indication that
those compounds with the greatest in
vitro cytotoxicity also show the most
neurotoxicity. However, when the 4 com-
pounds were administered at a dose level
designed, as far as possible, to reproduce
the exposure achieved in patients with
misonidazole (Dische et al., 1977) as
opposed to the unrealistically large single
doses used in the first experiment already
described, the dependence of NCV was
markedly different (Fig. 5c, d). There was
no clear correlation with aerobic cyto-
toxicity in vitro, but the octanol/water
partition coefficient was more important
in determining neurotoxicity. Those com-
pounds showing a relatively higher lipid
solubility were more neurotoxic. From this
result it is reasonable to speculate that the
tissues at risk from the actions of these
compounds are those containing a high
concentration of lipid. The myelin sheath
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FIG. 5.-(a) Percentage reduction in NCV after single injections, plotted as a function of the octanol/
H20 partition coefficient of the 4 test compounds.
(b) Percentage reduction in NCV after a single injection, as a function of the concentration of each
compound required in vitro to reduce mammalian cell survival to 75% in 2 h.
(c) Percentage reduction in NCV after multiple injections, as a function of octanol/H20 partition
coefficient of the 4 test compounds.
(d) Percentage reduction in NCV after multiple injections as a function of the concentration
required in vitro to reduce mammalian cell survival to 50% after 7-14 days exposure.
of peripheral nerves is an obvious target,
and this is supported by electron-micro-
scopic evidence ofdamage to the myelin of
mouse sciatic nerve (Dawson & Monoghan,
1978) and human peripheral nerve
(Urtasun et al., 1978) after misonidazole.
While neurotoxicity is clearly a very
important side effect of these radio-
sensitizers, it is probably not the only one.
This is supported by the observation that
the acute LD50 values (Table) correlate
only very roughly with the reduction in
NCV after single doses.
CONCLUSIONS
In these experiments we have been able
to measure nerve conduction velocity in
the mouse with an accuracy which de-
tected changes of the order of 10%. The
method would seem to offer better reso-
lution than other physiological tests, and
has enabled the effects of "clinically
relevant" doses of radiosensitizers to be
detected and quantified. However, there
are a number of disadvantages which
ought to be considered before embarking
on any major drug-testing programme. It
is an invasive method requiring a large
number of experimental animals which do
not survive the tests; it is also restricted
to measurements of motor nerves, while
all the available clinical evidence suggests
that these neuropathies are principally
sensory. The need for large temperature
corrections is clearly a weakness of the
technique, particularly in view of the
large effect of the temperature on NCV,
and in the development of any future
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system accurate temperature control
should have a high priority. Finally,
the relative effects of the tested com-
pounds are not wholly consistent with
clinical experience to date. The relatively
large changes produced by metronidazole
in the multiple-dose experiment were
particularly surprising, as it can be ad-
ministered in considerably higher doses to
patients (by a factor of 3-5) than misoni-
dazole before encountering neurological
complications (Urtasun et al., 1975; Dische
et al., 1977; Urtasun et al., 1977; Karim,
1978; Kogelnik et al., 1978). In addition,
the wide discrepancy between the toxicity
of metronidazole given acutely and as
multiple fractions cannot be explained.
In an attempt to overcome some of the
shortcomings of the present system a non-
invasive end-point is being developed, to
investigate further the problem of neuro-
toxicity in existing and potential radio-
sensitizers. The method depends on
measuring the reaction time between a
mild sensory stimulus (tactile and audi-
tory) and the change in electrical activity
which this elicits inthe muscle ofthethigh,
as detected by recording electrodes placed
on the skin.
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APPENDIX I
ELECTRONICS
A block diagram of the measuring equip-
ment is shown in Fig. 6. A manual trigger
pulse initiates the measurement cycle, in
which the first stimulus pulse is generated at
the end ofa Ims reset period. The interpulse
delay time is started synchronously, and a
clock gate is opened which sends pulses from
a 1MHz quartz-crystal oscillator into a 4-
decade up/down counter, set initially in the
"count up" mode. The muscle response is
detected by a high-impedance buffer amplifier
close to the muscle and a variable gain AC
coupled amplifier. The resultant waveform is
fed to a threshold circuit which produces a
short pulse (10 us) w-hen a manually set
threshold level is exceeded. This pulse closes
the gate. The number in the counter thus
corresponds to the stimulus-response delay
time. This number is subsequently stored in
the output memory and displayed on a
4-digit display (maximum count 9-999 ms)
At the end of the interpulse delay (0-2-20 s),
the up/down counter is set in the "count
down" mode, the second stimulus pulse is
generated and the measurement process
repeated. This time, however, the counter is
decremented at the 1MHz rate so that the
final number in the counter corresponds to
the difference between the response times
from the 2 stimulation points alongthe nerve.
The first stimulus point is arranged to be
further away so that the time difference is
Stimulus Response
electrodes electrode
FIG(1. 6. Block (liagram of the measurement electronics. The frequency response of the response
amplifier was 3 Hz-200 KHz and its voltage gain variable over the range x 1- x 300. This enabled
the "close gate" pulse superimposed on the response to be always 10% of the vertical display.
The stimulus amplifiers had an off-load voltage output of -90 V. The oscilloscope. trigger could be
delaye(d relative to the stimulus to enable the iresponse to be vieNed on a faster sweep.
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always positive. Ifthe inter-electrode distance
is known, the final count is thus an indication
of nerve conduction velocity. The counter
output is stored and displayed at the end of
a 10s delay, initiated at the end of the
measurement, or upon a manual command.
The electronic subtraction of the 2 stimulus/
response time delays is the only major
improvement over the system previously
described in Hirst et al. (1978).
Circuitry which inhibits the generation of
the "close gate" pulse during the stimulus
period is also provided. This prevents any
stimulus artefact, as picked up by the re-
sponse electrode, from interfering with the
operation ofthe logic. To facilitate the setting-
up of the threshold control, a proportion of
the "close gate" impulse was added to the
response waveform as displayed by the
oscilloscope. The position of the threshold
point along the waveform could thus be
easily observed. As far as the stimulus pulse
was concerned, both the width and the
amplitude ofthe pulse were variable (2-100 tus
and 0-50 uA negative respectively).
The circuitry is built in a modular format,
conveniently subdivided into a display
module, a control logic and up/down counter
module and an analogue input/output
module. The logic sections were assembled
using the RCA C04000 family of integrated
circuits.
APPENDIX II
TISSUE EXPOSURE TO DRUG
It is not possible to produce in the mouse
the precise tissue exposure to misonidazole
achieved in man. This is mainly because the
half-life in man is at least 6 x that in the
mouse (Flockhart et al., 1978). However, in
the chronic exposure experiment an attempt
was made to match 2 aspects of the drug-
exposure pattern.
(1) Peak concentration
A dose of 0 15 mg/g of misonidazole was
found to give a peak plasma level of 70 0+
2-5 Hug/ml in the strain of mice used for the
present experiments. This dose was chosen to
give a similar peak plasma level to that
measured in patients during a recent clinical
trial (Dische et al., 1977).
(2) Integrated exposure
The interval between drug doses was
chosen so that the total area under the plasma
concentration/time plot was the same as that
for patients receiving 6 fractions in 18 days.
36 fractions in 18 days was considered to be a
good approximation, although it obviously
had more fluctuations than in the corre-
sponding 6 fractions exposure in patients.
This injection schedule w%as then used for all
the compounds tested.
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